Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 11/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979865 | 0.95 | PRKCQ (0.38) | FGFR4PRKCQCHEK1PRKCD | |
| SCHEMBL19630148 | 0.95 | PRKCQ (0.38) | FGFR4PRKCQCHEK1PRKCD | |
| SCHEMBL29979050 | 0.82 | PRKCQ (0.41) | FGFR4PRKCQKDM4ECHEK1PRKCD | |
| SCHEMBL19629910 | 0.82 | PRKCQ (0.41) | FGFR4PRKCQKDM4ECHEK1PRKCD | |
| SCHEMBL16668807 | 0.80 | NCF1 (0.46) | FGFR4 | |
| SCHEMBL16668835 | 0.78 | FGFR4 (0.36) | FGFR4PRKCQPRKCD | |
| SCHEMBL16668108 | 0.77 | FGFR4 (0.38) | FGFR4PRKCQPRKCD | |
| SCHEMBL23300674 | 0.76 | ENPP1 (0.41) | FGFR4 | |
| SCHEMBL22023323 | 0.76 | PRKCQ (0.56) | PRKCQCHEK1PRKCD | |
| SCHEMBL16667970 | 0.76 | FGFR4 (0.37) | FGFR4PRKCQCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| CN-113234072-B | FGFR4 inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-113105454-B | FGFR4 inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| CN-109745321-A | Pharmaceutical composition comprising FGFR4 inhibitor | 上海翰森生物医药科技有限公司 | 2019-05-14 | — | — | CN | disclosed |
| EP-3444250-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
| EP-3444250-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2019-02-20 | — | — | EP | disclosed |
| CN-109071532-A | FGFR4 inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017198149-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | 江苏豪森药业集团有限公司 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276451-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885PRKCQ 2525/4885KDM4E 1217/4885 |
| US-11667631-B2 | FGFR4 inhibitor, preparation method therefor, and applications thereof | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885PRKCQ 2525/4885KDM4E 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.